Grimley, Michael
Davies, Stella M.
Shrestha, Archana
Shova, Amy
Asnani, Monika
Kent, Michael
Sayani, Farzana
Quinn, Charles T. https://orcid.org/0000-0002-2372-2175
Niss, Omar
Lutzko, Carolyn
Mehta, Parinda A.
Khandelwal, Pooja
Little, Courtney
Chandra, Sharat
Felker, Sydney
Chi, Mengna https://orcid.org/0000-0001-7439-1663
Kalfa, Theodosia A.
Knight-Madden, Jennifer https://orcid.org/0000-0002-0939-1648
Arumugam, Paritha I.
Ramos, Kristie N.
Witting, Scott https://orcid.org/0000-0002-7710-7928
Latham, Teresa
Bushman, Frederic D. https://orcid.org/0000-0003-4740-4056
Malik, Punam https://orcid.org/0000-0002-8942-2108
Funding for this research was provided by:
Doris Duke Charitable Foundation (Clinical Scientist Award)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (None)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (Gene Therapy Resource Program RSA 1141)
Cincinnati Children's Hospital Medical Center (Research Foundation Grant)
Aruvant Sciences, Inc. (Research Grant) Charles H Dater Foundation
Article History
Received: 23 August 2024
Accepted: 20 March 2025
First Online: 26 May 2025
Competing interests
: P.M. has received royalties, research funding and consulting fees from Aruvant Sciences. P.K. is the Co-Chair of the CIBMTR GVHD working committee; C.T.Q. is a Member of the SCD Task Force, American Society of Hematology (ASH); J.K.-M. is a member of the Hydroxyurea Guidelines Development Group for SCD, ASH; T.A.K. is a member of the Scientific Committee on Blood Disorders in Childhood, ASH; S.M.D. is on the Advisory Board of Polarean; P.M. has memberships on the Global Gene Therapy Initiative, Publications Committee, American Society of Cell and Gene Therapy (ASGCT), and the Hematopoiesis and PID Committee, European Society of Gene and Cell Therapy. She is also on the ASGCT Board of Directors. The other authors declare no competing interests.